Bill > HR2427

Introduced Session

To amend the Federal Food, Drug, and Cosmetic Act with respect to advisory committee process. This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to provide an opportunity for a person whose premarket submission for a medical device is subject to review by a classification panel to provide recommendations on the expertise needed among the members of the panel. The FDA must consider these recommendations and ensure that panels include at least two members with expertise clinically relevant to the device and at least one member who is knowledgeable about the technology of the device. The person whose device is under review may designate a representative (who may be accompanied by experts) to participate in panel meetings.

Committee Categories

John Shimkus (R)*, 

Referred to the Subcommittee on Health. (on 05/22/2015)

Official Document